Electronic supplementary information (ESI) available: full experimental details of probe synthesis and characterization, relaxivity measurement, cell culture, animal protocol and MR imaging. ‡ These authors contributed equally to the work. 
effectively outcompete free cysteine, we have optimized our controlled self-assembly strategy by turning the intermolecular polymerization system to an intramolecular macrocyclization chemistry. 27 This new system has been successfully demonstrated by imaging enzyme activity both in cells and living mice with fluorescence 28, 29 and PET probes 30 . In this study, we show that this optimized self-assembly strategy can be applied to develop a caspase-3/7-activatable Gd-based MRI probe.
Caspases are a family of cysteine proteases that play essential roles in apoptosis by initiating, regulating, and executing downstream proteolytic events during programmed cell death. It has been recognized that radio-and chemotherapy-induced tumor cell death often leads to the activation of caspase-3/7, an "executioner" for cell apoptosis. 31, 32 Therefore, caspase-3/7 has become an important early biomarker for evaluating apoptosis-promoting antitumor therapies, imaging of which can provide invaluable predictive information regarding therapeutic efficacy and anti-cancer drug selection. 33 A number of activatable fluorescent probes [34] [35] [36] [37] and radiolabeled PET tracers 30, [38] [39] [40] have been developed for imaging of caspase-3/7 activity in apoptotic cells and living mice. Recently, an activatable thullium-based paramagnetic chemical exchange saturation transfer (PARACEST) MRI probe 41 and paramagnetic relaxation-based 19 F MRI probes 42, 43 have also been reported, however, their ability to image caspase-3 activity in cells and in vivo is compromised by the relatively lower detection sensitivity of PARACEST and 19 F MRI agents. Here we report a caspase-3/7-activatable MRI probe that employs chelated Gd, one of the most common clinically used MRI contrast agents to enhance contrast, to non-invasive MR imaging of caspase-3/7 activity in drug-induced apoptotic tumors in living mice.
Results and discussion
Design of caspase-3/7 activatable and control MRI probes which consists of: a 2-cyano-6-hydroxyquinoline (CHQ) and a D-cysteine residue for efficient biocompatible cyclization, a DEVD peptide recognized by active caspase-3/7, a disulfide bond reduced by intracellular glutathione (GSH), and a Gd-DOTA monoamide chelate as the MRI reporter.
The reducing intracellular environment in mammalian cells (i.e. up to 10 mM GSH) would provide a simple, convenient approach to control the intracellular reduction of the disulfide bond in 1. Disulfide
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Chemical Science Accepted Manuscript reduction and caspase-3/7 activation that initiates DEVD peptide cleavage will trigger intramolecular cyclization of 1. Unlike the flexible precursor 1, the macrocyclic product 2 is more rigid and hydrophobic, and can further self-assemble into GdNPs, as a result of the increased intermolecular interactions (i.e. hydrophobic interaction, π-π stacking). GdNPs have an increased r 1 relaxivity relative to the unactivated probe, presumably due to an increased τ R . The control probe 1-ctrl has a quinolin-6-yl ring replacing the CHQ moiety in 1, preventing intramolecular cyclization following DEVD peptide cleavage by caspase-3 and abrogating GdNPs formation. Therefore, 1-ctrl is able to discern the relative contributions of peptide cleavage and triggered self-assembly to the mechanism of MR contrast enhancement. Both probes were synthesized and characterized as outlined in Supporting Information (ESI: Scheme S1-3). ( Fig. 2a) . In contrast, after 24 h of incubation of 1-ctrl with caspase-3, only the DEVD peptide cleaved and disulfide reduced products 1-ctrl-r were observed (ESI: Fig. S1 ).
The formation of GdNPs in solution after caspase-3 activation was measured by dynamic light scattering (DLS), showing the aggregation of particles with a mean hydrodynamic radius of ~164 nm (Fig. 2b) . Transmission electron microscopy (TEM) showed the shapes of separated GdNPs with diameters ranging from 50 to a few hundred nanometers (Fig. 2c) . The presence of Gd in the particles was further verified by energy-dispersive X-ray (EDX) spectroscopy (ESI: Fig. S2 ). 
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Water proton r 1 relaxivities of 1 and 1-ctrl before and after caspase-3 incubation were then measured at 1, 1.5 and 3 T (ESI: Fig. S3 ). The relaxivity of isolated cyclized products 2-I and 2-II, was also measured for comparison. As shown in Table 1 , the relaxivities of 1 and 1-ctrl were similar and higher than Dotarem at all three magnetic fields. The larger relaxivities are in line with a larger molecular size of 1 and 1-ctrl compared to Dotarem, resulting in longer τ R . As expected, caspase-3 incubation enhanced the relaxivity of probe 1, probably due to a further increase in τ R after the formation of GdNPs in solution 26, 44 . ). In contrast, incubation of 1-ctrl with caspase-3 gave slightly reduced relaxivities (-7% at 1 T), which is expected given the decreased size of the cleaved, but non-cyclized, products. These results validate the rationale in our probe design: namely, that caspase-3 activated self-assembly of cyclized products from 1 into GdNPs generates higher per Gd relaxivity at low magnetic field strengths 45 , and that this self-assembly does not occur for cleaved products of 1-ctrl.
The higher relaxivity of 1 after caspase-3 activation was further demonstrated by T 1 -weighted MR imaging at 1.5 T (Fig. 3c ). Moreover, it should be noted that the isolated cyclized products 2-I and 2-II gave similar relaxivities compared to 1 upon caspase-3 incubation, indicating a high efficacy for capase-3 activation.
Next, the activation kinetics of 1 by caspase-3 was evaluated by monitoring the T 1 value change of probe 1 solution (200 μM) upon addition of caspase-3 (50 nM) over time in enzyme reaction buffer (Fig. 3a) . A gradual and quick reduction of T 1 value in solution was observed after incubation with caspase-3 from 0 to 5 h. This was further confirmed by HPLC measurement, showing a fast kinetics for caspase-3 catalyzed hydrolysis and macrocyclization of 1 (Fig. 3b) . Enzyme specificity was examined using both the T 1 -weighted imaging and T 1 value (1 T) measurement of 1 incubated with nine relevant subcellular proteases (caspase-1, 3, -7, -9, cathepsin B, D, L, S and legumain) in buffer.
Significantly brighter T 1 -weighted images were observed for both of the effector caspases (-3 and -7) that are activated during cell apoptosis and are capable of cleaving the same DEVD peptide Table 1 Fig . 3 
MR imaging of caspase-3/7 activity in drug-treated cancer cells
The cytotoxicity was firstly evaluated by incubation of viable HeLa cells with 1 at 250 μM for 24 h, and no adverse effects on cell viability were observed (ESI: Fig. S7 ). The apoptotic cell model was validated by treating HeLa cells with a broad-spectrum protein kinase inhibitor staurosporine (STS, 2 μM) as reported previously.
29,46
Caspase-3/7 assays confirmed that the lysates of STS-treated cells showed ~10.5-fold higher caspase-3/7 activity than that of non-treated viable cells (ESI: Fig. S8 ). The enhanced caspase-3/7 activity was further confirmed by the incubation of STS-treated and non-treated HeLa cells with a caspase-3/7-sensitive fluorescent probe (1-FITC), which showed an intense green fluorescence only in apoptotic cells (ESI: Fig. S9 ).
Next, the cellular uptake of Gd was measured by inductively coupled plasma mass spectrometry (ICP-MS) analysis of the amount of Gd in viable and apoptotic cells after incubation with 1 (50, 100, 250 μM) for 24 h. This showed a concentration-dependent uptake in both viable and apoptotic cells (Fig. 4a) . The cellular uptake of Gd in STS-treated cells was ~0.5 fmol/cell with 250 μM of 1, which was ~6.6-fold of that in non-treated cells. This uptake enhancement can be inhibited by the caspase inhibitor Z-VAD-fmk (50 μM), confirming the caspase-dependent accumulation of 1 in apoptotic cells. As controls, the incubation of STS-treated cells with either 1-ctrl or Dotarem gave much lower uptakes of Gd (Fig. 4B ). An MRI study of the cell pellets at 1 T showed a significantly (~3-fold) reduced T 1 value in STS-treated cells after incubation with 1 (250 μM) as compared to non-treated cells (Fig. 5A ). There was no significant reduction in T 1 value between STS-treated and non-treated cells incubated with Dotarem. The much shorter T 1 value was consistent with the results of T 1 -weighted images of cell pellets as shown in Fig. 5b , where STS-treated cells appeared brighter 
MR imaging of drug-induced tumor death in mice
The mechanism of action of C-SNAM (1) for imaging of caspase-3/7 activity in chemotherapy-induced apoptotic tumor cells in vivo is illustrated in Fig. 6a . After intravenous administration, probe 1 can rapidly extravasate and penetrate into tumor tissue due to its relatively small size. In viable tumor cells, pro-caspase-3/7 dominates, which cannot cleave DEVD caging peptide from 1, leading to rapid diffusion of 1 away from the tumor. In apoptotic tumor cells, the increase in cell membrane permeability upon progression through apoptosis to cell death is well characterized [47] [48] [49] , enhancing the ability of 1 to partition into apoptotic tumor cells; pro-caspase-3 is efficiently converted to active caspase-3 which in turn cleaves the DEVD capping group, and the reductive intracellular microenvironment reduces the disulfide, the combination of which initiates the intramolecular cyclization and aggregation to form GdNPs. In addition to enhanced r 1 relaxivity, the GdNPs also show prolonged retention in chemotherapy-responsive tumors due to their large size.
Both features enhance the resultant MRI contrast for in vivo applications. ICP-MS analysis of Gd uptake in tumors confirmed significantly higher Gd levels in treated tumors after injection of 1 (Fig. 7) . The enhanced MR signals in treated tumors with 1 correlated well with the caspase-3/7 level detected in tumors (ESI: Fig. S10 ). In addition, we did not observe obvious signs of toxicity in mice during experiments and up to two weeks after probe injection. The above results indicate the feasibility of probe 1 for rapid and non-invasive monitoring of tumor response to chemotherapy in living mice. Currently, on-going work is focused on further evaluation of the probe in more clinically relevant animal models as well as its long-term toxicity in vivo. These studies will provide valuable insights for the translational potential of C-SNAM. 
Conclusions
In conclusion, we have reported a novel caspase-3/7-activatable Gd-based MRI probe C-SNAM for imaging chemotherapy-induced tumor apoptosis in mice. This activatable MRI probe undergoes biocompatible intramolecular cyclization and subsequent self-assembly into GdNPs upon reduction and caspase-3/7 activation, resulting in enhanced r 1 relaxivity (86%) and longer retention in apoptotic tumors. The controlled self-assembly strategy of using caspase-3/7 to activate a small molecule contrast agent to achieve significantly enhanced r 1 relaxivities and stronger MR signal may serve as a general approach to design activatable MRI probes for molecular imaging of enzyme activity in vivo. ) was injected i.v., and the mice were sacrificed after 1 h. The tumors were resected, weighted, and digested with 69% HNO 3 .
The total Gd amount was analyzed by ICP-MS, and the tumor Gd uptake was normalized to tumor weight. Each data point and error bar represents the mean and standard deviation of 5 mice.
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